Sarcoma  >>  temozolomide  >>  Phase 2
Welcome,         Profile    Billing    Logout  

26 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
temozolomide / Generic mfg.
NCT02511132: A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Completed
2b
22
US
Vigil, formerly known as FANG™, bi-shRNAfurin and GMCSF Autologous Tumor Cell Immunotherapy, Temozolomide, TEMODAR, Irinotecan, CAMPTOSAR, Gemcitabine, GEMZAR, Docetaxel, TAXOTERE
Gradalis, Inc.
Ewing's Sarcoma
11/18
12/20
NCT00194766: Continuous Temozolomide in Patients With Advanced or Metastatic Soft Tissue Sarcoma or Metastatic Breast Cancer

Completed
2
35
US
Temozolomide
University of Washington, Schering-Plough
Breast Cancer, Soft Tissue Sarcoma
 
12/06
NCT00365222: Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma

Terminated
2
1
US
Temozolomide, Temodar
H. Lee Moffitt Cancer Center and Research Institute, Schering-Plough
Glioblastoma, Gliosarcoma
06/07
06/07
NCT00187486: Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors

Completed
2
66
US
Tarceva, erlotinib, Temodar, temozolomide, Radiation Therapy
University of California, San Francisco, Genentech, Inc.
Glioblastoma Multiforme, Gliosarcoma
03/11
03/11
NCT00597402: Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas

Completed
2
125
US
Avastin, Bevacizumab, Temozolomide, Temodar, Radiation Therapy (XRT), Irinotecan, CPT-11, Camptosar
Duke University, Genentech, Inc., Schering-Plough
Glioblastoma, Gliosarcoma, Brain Tumor
08/11
05/13
NCT00657267: Dose-Intense Temozolomide in Recurrent Glioblastoma

Completed
2
58
US
Temozolomide, Temodar
Patrick Y. Wen, MD, Brigham and Women's Hospital, Massachusetts General Hospital, University of Pennsylvania, Wake Forest University Health Sciences, Tufts Medical Center, Dartmouth-Hitchcock Medical Center, Schering-Plough
Glioblastoma, Gliosarcoma
11/11
10/13
NCT00612339: Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas

Completed
2
41
US
Avastin and Temozolomide, Avastin - Bevacizumab, Temozolomide - Temodar
Duke University, Genentech, Inc., Schering-Plough
Glioblastoma, Gliosarcoma
05/12
05/12
NCT01004874: Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

Completed
2
80
US
Bevacizumab, Avastin, Temozolomide, Temodar, Radiation Therapy (XRT), Topotecan, Hycamtin
Duke University, Genentech, Inc., GlaxoSmithKline
Malignant Glioma, Glioblastoma, Gliosarcoma
07/12
11/21
NCT02599090: Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Withdrawn
2
0
US
Temozolomide, Radiation, Radiotherapy, XRT, Sorafenib, BAY43-9006
M.D. Anderson Cancer Center, Bayer
Glioblastoma, Gliosarcoma
12/12
12/12
NCT01186406: Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
2
41
US
Gliadel, Gliadel (carmustine wafers), Radiation Therapy, Avastin, Avastin (bevacizumab), Temodar, Temodar (temozolomide)
Duke University, Genentech, Inc., Eisai Inc.
Glioblastoma Multiforme, Gliosarcoma
06/14
06/14
NCT01313884: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated
2
3
US
Irinotecan, Camptosar, Campto, Vincristine, Oncovin, leurocristine, Temozolomide, Temodar, Temodal, Doxorubicin, Adriamycin, hydroxydaunorubicin, Cytoxan, Cyclophosphamide, Endoxan, Neosar, Procytox, Revimmune, cytophosphane, Pegfilgrastim, Neulasta
Stanford University, Amgen
Bone Cancer, Ewing's Sarcoma
07/14
07/14
NCT00883298: Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme

Completed
2
30
US
temozolomide and bevacizumab, Temodar, Avastin
Center for Neurosciences, Tucson, Genentech, Inc.
Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
12/14
12/14
NCT00998010: Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed
2
24
US
bortezomib + temozolomide+ radiation therapy
Jonsson Comprehensive Cancer Center, Millennium Pharmaceuticals, Inc.
Brain and Central Nervous System Tumors
03/16
04/18
NCT01692496 / 2012-002745-38: Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial

Completed
2
52
Europe
Pazopanib
Grupo Espanol de Investigacion en Sarcomas, GlaxoSmithKline
Advanced and / or Metastatic Liposarcoma
03/18
03/18
NCT01740258: Bevacizumab Beyond Progression (BBP)

Completed
2
68
US
Radiation Therapy, XRT, Temozolomide, temo, temodar, Bevacizumab, Avastin
Duke University, Genentech, Inc.
Malignant Glioma, Grade 4 Malignant Glioma, Glioblastoma, Gliosarcoma
11/19
11/19
NCT03746080: Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Active, not recruiting
2
21
US
Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, Whole-Brain Radiotherapy (WBRT), WBRT, whole-brain radiation therapy, whole-brain radiotherapy, Radiation Therapy, XRT, RT
Lawrence D Recht, Sanofi
Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
05/22
07/27
NCT01149850: Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed
2
50
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, anti-VEGF rhuMAb, Avastin, recombinant humanized anti-VEGF monoclonal antibody, rhuMAb VEGF, temozolomide, CCRG-81045, M & B 39831, SCH 52365, Temodal, Temodar, TMZ, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, microarray analysis, gene expression profiling, DNA methylation analysis
Jonsson Comprehensive Cancer Center, Genentech, Inc.
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
12/23
12/23
NCT05457829: Doxorubicin Hydrochloride Liposome Combined With Irinotecan Versus VIT Regimen in the Treatment of Pediatric Rhabdomyosarcoma

Not yet recruiting
2
88
NA
Doxorubicin Hydrochloride Liposome+Irinotecan, Temozolomide+Irinotecan+Vincristine
Sun Yat-sen University, CSPC Ouyi Pharmaceutical Co., Ltd.
Rhabdomyosarcoma, Child
06/26
07/26
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
02/27
09/28
NCT00402116: Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients

Completed
1/2
72
US
enzastaurin, LY317615, temozolomide, radiation therapy
Eli Lilly and Company, University of California, San Francisco
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma
12/09
12/09
NCT00734526: Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Terminated
1/2
18
US
Temozolomide, Radiation, Radiotherapy, XRT, Sorafenib, BAY43-9006
M.D. Anderson Cancer Center, Bayer
Glioblastoma, Gliosarcoma
12/12
12/12
NCT02052648: Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Hourglass Jan 2019 - Jun 2019 : Updated data from P1b trial for recurrent pediatric brain tumors
Checkmark In combination with temozolomide for malignant brain tumors at SNO 2015
Nov 2015 - Nov 2015: In combination with temozolomide for malignant brain tumors at SNO 2015
Checkmark Top-line data from P1b portion of P1b/2 trial in temozolomide-refractory primary malignant brain tumors at ASCO 2015
May 2015 - Jun 2015: Top-line data from P1b portion of P1b/2 trial in temozolomide-refractory primary malignant brain tumors at ASCO 2015
More
Completed
1/2
160
US
Indoximod, 1-methyl-D-tryptophan, D-1MT, Temozolomide, Temodar, Methazolastone, Bevacizumab, Avastin, Stereotactic Radiation, SRS or SRT
NewLink Genetics Corporation
Glioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
04/18
06/19
2021-005617-14: Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II) Estudio para evaluar la seguridad e identificar la dosis de ribociclib en combinación con temozolomida y topotecán (TOTEM) en pacientes (12 meses - 21 años) con tumores sólidos recidivantes o refractarios (Fase I) y evaluar la eficacia y seguridad en pacientes (12 meses - 21 años) con neuroblastoma recidivante o refractario (Fase II)

Ongoing
1/2
230
Europe, RoW
ribociclib, temozolomida 5 mg cápsulas duras, topotecan, temozolomida 20 mg cápsulas duras, temozolomida 100 mg cápsulas duras, temozolomida 140 mg cápsulas duras, temozolomida 180 mg cápsulas duras, temozolomida 250 mg cápsulas duras, LEE011, Powder for oral solution, Capsule, hard, Concentrate for solution for infusion, Temozolomid SUN & Temozolomid Accord, Potactasol & Hycamtin
Novartis Farmacéutica, S.A., Novartis Pharma AG, Novartis Pharma AG
relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years old neuroblastoma recidivante o refractario y otros tumores sólidos (incluyendo meduloblastoma, glioma de alto grado, tumores rabdoides malignos y rabdomiosarcoma) en pacientes con edades comprendidas entre los 12 meses y los 21 años, Recurrent solid tumors in patients from 12 months to 21 years old Tumores sólidos recurrentes en pacientes con edades comprendidas entre los 12 meses y los 21 años, Diseases [C] - Cancer [C04]
 
 
NCT01837862: A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

Recruiting
1/2
36
US
Mebendazole, Vermox, Vincristine, Oncovin, Carboplatin, Paraplatin, Temozolomide, Temodar, Bevacizumab, Avastin, Irinotecan, CPT-11, Camptosar
Julie Krystal, Janssen Pharmaceuticals
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma, Pleomorphic Xanthoastrocytoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliosarcoma, Diffuse Intrinsic Pontine Glioma, DIPG, Low-grade Glioma, Brainstem Glioma
04/24
04/25
NCT03709680 / 2021-003444-25: Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting
1/2
128
Europe, Canada, US, RoW
Palbociclib, Ibrance, Temozolomide, Temodar, Irinotecan, Campto, Topotecan, Hycamtin, Cyclophosphamide, Cytoxan
Pfizer, Children's Oncology Group (COG)
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
08/24
02/25
NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25

Download Options